Volume 27, Number 11—November 2021
Research Letter
Fatal Systemic Capillary Leak Syndrome after SARS-CoV-2 Vaccination in Patient with Multiple Myeloma
Table
Clinical measures | Reference range | Test results after SCLS episodes |
|
---|---|---|---|
5 mo earlier | Postvaccination | ||
Leukocytes, ×103/mm3 | 4–10 | 6.88 | 29.42 |
Hemoglobin, g/dL | 13–17 | 14.7 | 22.7 |
Hematocrit, % | 40–52 | 44.3 | 63.7 |
Platelet, ×103/mm3 | 140–440 | 259 | 133 |
Albumin, g/dL | 3.5–5.0 | 4.8 | 3.3 |
Blood urea nitrogen, mg/dL | 8–23 | 13.6 | 33 |
Creatinine, mg/dL | 0.7–1.2 | 0.94 | 2.0 |
Aspartate transaminase, IU/L | 10–35 | 22 | 30 |
Alanine transferase, IU/L | 0–40 | 14 | 4 |
Total bilirubin, mg/dL | 0.1–1.2 | 0.5 | 1.46 |
Calcium, mg/dL | 8.6–10.6 | 10.0 | 8.9 |
Erythrocyte sedimentation rate, mm/h | 0–20 | Not done | 13 |
C-reactive protein, mg/dL | 0–0.5 | Not done | 2.371 |
Procalcitonin, ng/ml | 0–5 | Not done | 0.641 |
Troponin I, ng/mL | 0–0.04 | Not done | 0.017 |
Creatine kinase myocardial band, ng/mL | 0.6–6.3 | Not done | 3.5 |
N terminal-pro B-type natriuretic peptide, pg/mL | 0–125 | 35.1 | 4,427 |
Lactic acid, mmol/L | 0.5–1.6 | Not done | 5.4 |
Creatine phosphokinase, IU/L | 1–171 | Not done | 276 |
*Vaccine was Ad26.COV2.S (Johnson & Johnson/Janssen, https://www.jnj.com). SCLS, systemic capillary leak syndrome.
Page created: August 24, 2021
Page updated: October 19, 2021
Page reviewed: October 19, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.